Trending...
- Still Using Ice? FrostSkin Reinvents Hydration
- Cold. Clean. Anywhere. Meet FrostSkin
- Don't Get Burned by High Heater Prices in Philly This Winter!
PHILADELPHIA, Oct. 22, 2024 ~ A recent study conducted by researchers at Children's Hospital of Philadelphia (CHOP) has shown the potential for rapid testing of cytokine levels to aid in distinguishing between different diseases with similar symptoms. The findings, published in the Journal of Allergy and Clinical Immunology, demonstrate the impact this testing can have on clinical practice.
The study, led by Dr. Michele P. Lambert, Medical Director of the Special Coagulation Laboratory and attending physician in the Division of Hematology at CHOP, focused on the use of serum cytokine panels in pediatric clinical practice. Cytokines are signaling proteins that regulate inflammation and coordinate immune responses.
During the COVID-19 pandemic, doctors faced a challenge in distinguishing between multisystem inflammatory syndrome in children (MIS-C) and acute, severe COVID-19 infection. Both conditions present with similar initial symptoms such as high fever and changes in blood pressure, but require very different courses of treatment.
Dr. Lambert explains, "We wanted to see what clinicians were able to do with this information if it was returned rapidly and whether results would change clinical decision making or muddy the waters and create confusion."
More on The PennZone
The study found that nearly 30% of clinicians changed how they managed disease in children after receiving cytokine level information. In 18.8% of cases, the diagnosis was changed or informed by the results, while management of the patient was changed or informed in 29.8% of cases.
One key finding was that specific disease states had clear cytokine patterns. For example, higher levels of interferon gamma (IFNg) and lower levels of interleukins 6 and 8 (IL-6 and IL-8) suggested a more robust inflammatory response, while a reverse in those levels indicated bacterial or viral sepsis.
Dr. Lambert emphasizes the potential life-saving impact of these results: "The results of a cytokine panel could potentially save lives: supporting antibiotics or immune suppression, but only if we have the results fast enough."
The study also highlights the importance of collaboration between clinicians and clinical laboratories in providing the best care for patients. As Dr. Lambert notes, "The evolution of our response time and our understanding of the value of these biomarkers demonstrates how important it is for clinicians and clinical laboratories to collaborate to provide the best care possible for patients."
With ongoing advancements in technology and understanding, rapid testing of cytokine levels has the potential to greatly impact clinical practice and improve patient outcomes. The study, titled "Serum Cytokine Panels in Pediatric Clinical Practice," was published online on September 18, 2024, with a DOI of 10.1016/j.jaci.2024.08.030.
For further information or inquiries, please contact Amanda DiPaolo Bradley at [insert contact information].
The study, led by Dr. Michele P. Lambert, Medical Director of the Special Coagulation Laboratory and attending physician in the Division of Hematology at CHOP, focused on the use of serum cytokine panels in pediatric clinical practice. Cytokines are signaling proteins that regulate inflammation and coordinate immune responses.
During the COVID-19 pandemic, doctors faced a challenge in distinguishing between multisystem inflammatory syndrome in children (MIS-C) and acute, severe COVID-19 infection. Both conditions present with similar initial symptoms such as high fever and changes in blood pressure, but require very different courses of treatment.
Dr. Lambert explains, "We wanted to see what clinicians were able to do with this information if it was returned rapidly and whether results would change clinical decision making or muddy the waters and create confusion."
More on The PennZone
- Kobie Wins for AI Innovations in the 2026 Stevie® Awards for Sales & Customer Service
- Author Jeff Bogle to Host Street Cats Mediterranean Cruise Featuring Cat Behaviorist Molly DeVoss
- Berman | Sobin | Gross LLP Celebrates 35 Years of Advocating for Maryland's Injured Workers and Families
- Art of Whiskey Hosts 3rd Annual San Francisco Tasting Experience During Super Bowl Week
- Kilmaine Saints to Anchor St. Patrick's Day Weekend with Live Album Recording at XL Live
The study found that nearly 30% of clinicians changed how they managed disease in children after receiving cytokine level information. In 18.8% of cases, the diagnosis was changed or informed by the results, while management of the patient was changed or informed in 29.8% of cases.
One key finding was that specific disease states had clear cytokine patterns. For example, higher levels of interferon gamma (IFNg) and lower levels of interleukins 6 and 8 (IL-6 and IL-8) suggested a more robust inflammatory response, while a reverse in those levels indicated bacterial or viral sepsis.
Dr. Lambert emphasizes the potential life-saving impact of these results: "The results of a cytokine panel could potentially save lives: supporting antibiotics or immune suppression, but only if we have the results fast enough."
The study also highlights the importance of collaboration between clinicians and clinical laboratories in providing the best care for patients. As Dr. Lambert notes, "The evolution of our response time and our understanding of the value of these biomarkers demonstrates how important it is for clinicians and clinical laboratories to collaborate to provide the best care possible for patients."
With ongoing advancements in technology and understanding, rapid testing of cytokine levels has the potential to greatly impact clinical practice and improve patient outcomes. The study, titled "Serum Cytokine Panels in Pediatric Clinical Practice," was published online on September 18, 2024, with a DOI of 10.1016/j.jaci.2024.08.030.
For further information or inquiries, please contact Amanda DiPaolo Bradley at [insert contact information].
Filed Under: Business
0 Comments
Latest on The PennZone
- FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
- $2.7 Million 2025 Revenue; All Time Record Sales Growth; 6 Profitable Quarters for Homebuilding Industry: Innovative Designs (Stock Symbol: IVDN)
- Beyond Spots & Dots Commits $50,000 to Penn State University Communications Students
- CCHR: Decades of Warnings, Persistent Inaction; Studies Raise New Alarms on Psychiatric Drug Safety
- PRÝNCESS Builds Anticipation With "My Nerves" — A Girls-Girl Anthem
- Arbutus Medical Raises C$9.3M to Accelerate Growth of Surgical Workflow Solutions Outside the OR
- From Sleepless Nights to Sold-Out Drops: Catch Phrase Poet's First Year Redefining Motivational Urban Apparel
- Cold. Clean. Anywhere. Meet FrostSkin
- How Specialized Game Development Services Are Powering the Next Wave of Interactive Entertainment
- Brain Drain Unlimited Strengthens Legal Advocacy with Advanced Training from Villanova University
- Don't Settle for a Lawyer Who Just Speaks Spanish. Demand One Who Understands Your Story
- Dan Williams Promoted to Century Fasteners Corp. – General Manager, Operations
- Ski Johnson Inks Strategic Deals with Three Major Food Chain Brands
- NIL Club Advances Agent-Free NIL Model as Oversight Intensifies Across College Athletics
- Pallet Company Partners with Internet Marketing Company
- Atlanta Magazine Names Dr. Rashad Richey One of Atlanta's Most Influential Leaders in 2026 as the FIFA World Cup Approaches
- Apostle Margelee Hylton Announces the Release of Third Day Prayer
- Slotozilla Reports Strong Q4 Growth and Sigma Rome Success
- "Lights Off" and Laughs On: Joseph Neibich Twists Horror Tropes in Hilariously Demonic Fashion
- Families Gain Clarity: Postmortem Pathology Expands Private Autopsy Services in St. Louis